-
Je něco špatně v tomto záznamu ?
FasL Modulates Expression of Mmp2 in Osteoblasts
E. Svandova, B. Vesela, H. Lesot, J. Sadoine, A. Poliard, E. Matalova,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
PubMed
30283358
DOI
10.3389/fphys.2018.01314
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
FasL is a well-known actor in the apoptotic pathways but recent reports have pointed to its important novel roles beyond cell death, as observed also for bone cells. This is supported by non-apoptotic appearance of FasL during osteogenesis and by significant bone alterations unrelated to apoptosis in FasL deficient (gld) mice. The molecular mechanism behind this novel role has not yet been revealed. In this report, intramembranous bone, where osteoblasts differentiate directly from mesenchymal precursors without intermediary chondrogenic step, was investigated. Mouse mandibular bone surrounding the first lower molar was used as a model. The stage where a complex set of bone cells (osteoblasts, osteocytes, osteoclasts) is first present during development was selected for an initial examination. Immunohistochemical staining detected FasL in non-apoptotic cells at this stage. Further, FasL deficient vs. wild type samples subjected to osteogenic PCR Array analysis displayed a significantly decreased expression of Mmp2 in gld bone. To examine the possibility of this novel FasL-Mmp2 relationship, intramembranous bone-derived osteoblastic cells (MC3T3-E1) were treated with anti-FasL antibody or rmFasL. Indeed, the FasL neutralization caused a decreased expression of Mmp2 and rmFasL added to the cells resulted in the opposite effect. Since Mmp2-/- mice display age-dependent alterations in the intramembranous bone, early stages of gld mandibular bone were examined and age-dependent phenotype was confirmed also in gld mice. Taken together, the present in vivo and in vitro findings point to a new non-apoptotic function of FasL in bone development associated with Mmp2 expression.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19001673
- 003
- CZ-PrNML
- 005
- 20190109122326.0
- 007
- ta
- 008
- 190107s2018 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fphys.2018.01314 $2 doi
- 035 __
- $a (PubMed)30283358
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Svandova, Eva $u Department of Physiology, University of Veterinary and Pharmaceutical Sciences, Brno, Czechia. Laboratory of Molecular Morphogenesis, Institute of Animal Physiology and Genetics, The Czech Academy of Sciences, Brno, Czechia.
- 245 10
- $a FasL Modulates Expression of Mmp2 in Osteoblasts / $c E. Svandova, B. Vesela, H. Lesot, J. Sadoine, A. Poliard, E. Matalova,
- 520 9_
- $a FasL is a well-known actor in the apoptotic pathways but recent reports have pointed to its important novel roles beyond cell death, as observed also for bone cells. This is supported by non-apoptotic appearance of FasL during osteogenesis and by significant bone alterations unrelated to apoptosis in FasL deficient (gld) mice. The molecular mechanism behind this novel role has not yet been revealed. In this report, intramembranous bone, where osteoblasts differentiate directly from mesenchymal precursors without intermediary chondrogenic step, was investigated. Mouse mandibular bone surrounding the first lower molar was used as a model. The stage where a complex set of bone cells (osteoblasts, osteocytes, osteoclasts) is first present during development was selected for an initial examination. Immunohistochemical staining detected FasL in non-apoptotic cells at this stage. Further, FasL deficient vs. wild type samples subjected to osteogenic PCR Array analysis displayed a significantly decreased expression of Mmp2 in gld bone. To examine the possibility of this novel FasL-Mmp2 relationship, intramembranous bone-derived osteoblastic cells (MC3T3-E1) were treated with anti-FasL antibody or rmFasL. Indeed, the FasL neutralization caused a decreased expression of Mmp2 and rmFasL added to the cells resulted in the opposite effect. Since Mmp2-/- mice display age-dependent alterations in the intramembranous bone, early stages of gld mandibular bone were examined and age-dependent phenotype was confirmed also in gld mice. Taken together, the present in vivo and in vitro findings point to a new non-apoptotic function of FasL in bone development associated with Mmp2 expression.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vesela, Barbora $u Department of Physiology, University of Veterinary and Pharmaceutical Sciences, Brno, Czechia. Laboratory of Molecular Morphogenesis, Institute of Animal Physiology and Genetics, The Czech Academy of Sciences, Brno, Czechia.
- 700 1_
- $a Lesot, Hervé $u Laboratory of Molecular Morphogenesis, Institute of Animal Physiology and Genetics, The Czech Academy of Sciences, Brno, Czechia.
- 700 1_
- $a Sadoine, Jeremy $u Faculté de Chirurgie Dentaire, Université Paris Descartes, Paris, France.
- 700 1_
- $a Poliard, Anne $u Faculté de Chirurgie Dentaire, Université Paris Descartes, Paris, France.
- 700 1_
- $a Matalova, Eva $u Department of Physiology, University of Veterinary and Pharmaceutical Sciences, Brno, Czechia. Laboratory of Molecular Morphogenesis, Institute of Animal Physiology and Genetics, The Czech Academy of Sciences, Brno, Czechia.
- 773 0_
- $w MED00174601 $t Frontiers in physiology $x 1664-042X $g Roč. 9, č. - (2018), s. 1314
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30283358 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190109122529 $b ABA008
- 999 __
- $a ind $b bmc $g 1365480 $s 1039796
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 9 $c - $d 1314 $e 20180919 $i 1664-042X $m Frontiers in physiology $n Front. physiol. $x MED00174601
- LZP __
- $a Pubmed-20190107